Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet?
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Pavord (Oxford, United Kingdom), G. Criner (Philadelphia, PA, United States of America), H. Kerstjens (Groningen, Netherlands), E. Bradford (Research Triangle Park, NC, United States of America), S. Schweiker Harris (Research Triangle Park, NC, United States of America), O. Keene (Stockley Park West, Uxbridge, Middlesex, United Kingdom), B. Mayer (Stockley Park West, Uxbridge, Middlesex, United Kingdom), D. Rubin (Stockley Park West. Uxbridge, Middlesex, United Kingdom), S. Yancey (Research Triangle Park, NC, United States of America), D. Bratton (Stockley Park, Uxbridge, Middlesex, United Kingdom). Eosinophils as a predictor of mepolizumab treatment responses in COPD. 1992

Member's Comments

No comment yet.

Related content which might interest you: Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Pharmacodynamic effect of benralizumab on blood basophils and serum biomarkers in adults with COPD with sputum eosinophilia Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Exacerbations of severe asthma in patients treated with mepolizumab Source: Eur Respir J, 52 (6) 1801127; 10.1183/13993003.01127-2018 Year: 2018 Increase in systemic IL-5 is associated with mepolizumab treatment failure in patients with severe asthma Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Clinical response to mepolizumab in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Eosinophil counts as a predictor of future COPD exacerbations in the DYNAGITO trial Source: International Congress 2019 – Eosinophils and FeNO in airway diseases Year: 2019 Plasma biomarkers and response to therapy at exacerbation of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 39s Year: 2007 Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD Source: Eur Respir J, 55 (5) 1902119; 10.1183/13993003.02119-2019 Year: 2020 Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018 The effect of anti-IL-5 therapy on sputum cells and cytokines in asthmatics Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Real-life treatment of severe eosinophilic asthma with mepolizumab Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Blood eosinophils as a marker of response to inhaled corticosteroids in COPD Source: Eur Respir J 2016; 47:1374-1382 Year: 2016 Neutrophils and spirometry changes in COPD patients treated with roflumilast Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease Year: 2015 Assessing bronchodilator response in patients with asthma and COPD using 19F-MRI Source: Virtual Congress 2020 – New imaging techniques applied to old problems Year: 2020 Cytokines concentrations in induced sputum of mild COPD patients. Correlation to clinical response to inhaled corticosteroids Source: Eur Respir J 2002; 20: Suppl. 38, 309s Year: 2002 Th2 related biomarkers as predictors of airway eosinophilia in optimally treated smoking asthmatics: An observational study. Source: International Congress 2017 – Techniques in biomarker selection Year: 2017 Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma Source: Eur Respir J, 55 (5) 1902259; 10.1183/13993003.02259-2019 Year: 2020 Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020